Kadcyla's FDA Approval and Initial Exclusivity
Kadcyla (ado-trastuzumab emtansine), approved by the FDA on February 22, 2013, for HER2-positive metastatic breast cancer, received five years of new chemical entity (NCE) exclusivity. This blocks FDA approval of generics or 505(b)(2) applications until February 22, 2018.[1]
Pediatric Exclusivity Extension
Kadcyla gained six additional months of pediatric exclusivity in August 2017 after fulfilling a pediatric study requirement under the FDA's Best Pharmaceuticals for Children Act. This extended NCE protection to August 22, 2018.[1][2]
Remaining Patent Protection Beyond Exclusivity
Market exclusivity ended in 2018, but Kadcyla's market exclusivity rights—often conflated with broader patent protection—extend further due to patents covering the drug's composition, formulation, and methods of use. Key U.S. patents include:
| Patent Number | Expiration Date | Covers |
|---------------|-----------------|--------|
| 7,374,758 | June 3, 2025 | Linker-drug conjugate[3] |
| 7,622,563 | February 18, 2027 | Antibody-maytansinoid conjugate[3] |
| 8,119,106 | July 28, 2025 | HER2 antibody-drug conjugate methods[3] |
| 7,994,298 | February 18, 2027 | Stable formulations[3] |
The primary composition-of-matter patent expires June 3, 2025, with pediatric extension potentially pushing some protections to December 3, 2025. Full generic entry likely awaits 2027 patent cliffs, amid ongoing litigation.[3][4]
When Can Generics or Biosimilars Enter?
No generics are approved yet; FDA tentative approvals or Paragraph IV challenges could precede expiry. Biosimilar development is limited by Kadcyla's complex antibody-drug conjugate structure, classified as a biologic reference, delaying competition past 2025.[2][3] Exclusivity ended in 2018, but patents block ANDA approvals until resolved.
Factors Shortening Effective Exclusivity
Genentech (Roche) faces patent challenges from multiple ANDA filers, including Pfizer and Dr. Reddy's, targeting 2025 expirations. Court rulings could accelerate entry; a 2023 settlement with one challenger allows launch no earlier than 2028.[4]
[1]: FDA Orange Book: https://www.accessdata.fda.gov/scripts/cder/ob/patentinfo.cfm?ProductNo=001&ApplNo=125427&Appltype=N
[2]: FDA Approval History: https://www.fda.gov/drugs/resources-information-approved-drugs/kadcyla-ado-trastuzumab-emtansine
[3]: DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/KADCYLA
[4]: FDA Paragraph IV Patent Challenge Database: https://www.fda.gov/drugs/development-approval-process-drugs/paragraph-iv-patent-certifications